Clariant boosts US pharmaceutical production with Clear Lake expansion
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Subscribe To Our Newsletter & Stay Updated